The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Recent updates from the MOMENTUM trial and the value of momelotinib for the treatment of MF
Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some updates from the Phase III MOMENTUM trial (NCT04173494), highlighting the important role of momelotinib and its ability to improve anemia in patients with myelofibrosis (MF). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
